Investment Rating - The investment rating for the company is "Buy" with a target price not specified [8] Core Views - The company achieved a revenue of 487 million yuan in the first half of 2025, representing a year-on-year increase of 21.7%, and a net profit attributable to shareholders of 220 million yuan, up 44.1% year-on-year [1] - The demand for animal health products remains strong due to improved profitability in the breeding sector, leading to a 17% increase in batch approvals in the first half of 2025 [2] - Vaccine sales have improved significantly, with a 43% year-on-year increase in batch approvals for vaccines in the first half of 2025, driven by strong industry demand and the launch of new products [3] - The company is focusing on research and development, with R&D expenses rising to 9.34% of total revenue, which has led to the successful launch of several new products [4] - The company is expected to benefit from the release of multiple new products in 2025-2027, with projected revenues of 1.22 billion, 1.31 billion, and 1.57 billion yuan, respectively, indicating a growth rate of 29%, 8%, and 19% [5] Financial Summary - The company reported a gross margin of 67% and a net margin of 45% for the first half of 2025, with improvements in profitability despite challenges in the downstream market [3] - The projected net profit for 2025 is 449 million yuan, with a year-on-year growth of 17.4%, and the corresponding P/E ratios for 2025, 2026, and 2027 are 20, 17, and 14, respectively [6][5]